<DOC>
<DOCNO>EP-0654997</DOCNO> 
<TEXT>
<INVENTION-TITLE>
COMPOSITIONS OF SUBSTITUTED AZASPIRANES AND METHODS OF TREATING PSORIASIS THEREWITH.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3140	A61K3140	A61K31403	A61K31403	A61K31415	A61K31415	A61K31435	A61K31435	A61K31445	A61K31445	A61K3146	A61K3146	A61P1700	A61P1700	C07D20900	C07D20996	C07D45100	C07D45102	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61P	A61P	C07D	C07D	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61P17	A61P17	C07D209	C07D209	C07D451	C07D451	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Invented is a method of treatment of psoriasis in a mammal in need thereof which comprises administering to such mammal an effective amount of a substituted azaspirane.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
SMITHKLINE BEECHAM CORP
</APPLICANT-NAME>
<APPLICANT-NAME>
SMITHKLINE BEECHAM CORPORATION
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BADGER ALISON MARY
</INVENTOR-NAME>
<INVENTOR-NAME>
GRISWOLD DON EDGAR
</INVENTOR-NAME>
<INVENTOR-NAME>
BADGER, ALISON MARY
</INVENTOR-NAME>
<INVENTOR-NAME>
GRISWOLD, DON EDGAR
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
Compositions of Substituted Azaspiranes and Methods of Treating Psoriasis therewithThis invention relates to a method of treatment of psoriasis in a mammal in need thereof which comprises administering to such mammal an effective amount of a substituted azaspirane.Background of the Invention Badger et al. U.S. Patent Application No. 4,963,557 discloses a class of suppressor cell inducing immunomodoulatory azaspirane compounds.Badger does not disclose or claim said compounds for the treatment of psoriasis.SUMMARY OF THE INVENTION This invention relates to a method of treatment of psoriasis in a mammal in need thereof which comprises administering to such mammal an effective amount of a compound of the formula
 (I) 

in which: m is 1 or 2;R! and R2 are the same or different and are selected from hydrogen or straight or branched chain alkyl, provided that the total number of carbon atoms contained by Rl and R^ when taken together is 4-10; or R* and R^ together form a cyclic alkyl group containing 3-7 carbon atoms; A is absent or present as C -C- alkyl; andR3 is a heterocyclic or heterobicyclic ring, said heterocyclic or heterobicyclic ring thereby containing up to 10 carbon atoms and from 1-3 heteroatoms of the formula^NR^, where R^ is absent or present as hydrogen, or a straight chain alkyl containing 1-3 carbon atoms; or a pharmaceutically acceptable salt, hydrate or solvate thereof.DETAILED DESCRIPTION OF THE INVENTION The term "treatment" and derivatives thereof as used in the specification and in the claims is meant that a mammal in need of antipsoriatic activity is cured of or provided with acceptable symptomatic relief from the disease.The term "effective amount" as used herein is meant the amount needed to effect treatment as defined above.The term "mammal" as used herein is meant warm-blooded vertebrate animals, including all that possess hair and suckle their young. Preferably said mammal is a human.This invention relates to a method of treatment of psoriasis in a mammal in need thereof which comprises administering to such mammal an effective amount of a compound of the formulain which: m is 1 or 2; 

4/04151- 3R! and R^ are the same or different and are selected from hydrogen or straight or branched chain alkyl, provided that the total number of carbon atoms contained by R and R^ when taken together is 4-10; or R^ and R^ together form a cyclic alkyl group containing 3-7 carbon atoms; A is absent or present as C1-C7 alkyl; andR3 is a heterocyclic or heterobicyclic ring, said heterocyclic or
</DESCRIPTION>
<CLAIMS>
/04151
What is claimed is: 18
1. A method of treatment of psoriasis in a mammal in need thereof which comprises administering to such mammal an effective amount of a compound of the formula

 in which: m is 1 or 2;
R! and R^ are the same or different and are selected from hydrogen or straight or branched chain alkyl, provided that the total number of carbon atoms contained by R^ and R^ when taken together is 4-10; or R^ and R^ together form a cyclic alkyl group containing 3-7 carbon atoms;
A is absent or present as C1-C7 alkyl; and
R3 is a heterocyclic or heterobicyclic ring, said heterocyclic or heterobicyclic ring thereby containing up to 10 carbon atoms and from 1-3 heteroatoms of the formula NR^, where R^ is absent or present as hydrogen, or a straight chain alkyl containing 1-3 carbon atoms; or a pharmaceutically acceptable salt, hydrate or solvate thereof.
The method of claim 1 wherein the mammal being treated is a human.
3. The method of claim 1 wherein the compound is selected from:
and 


 or a pharmaceutically acceptable salt, hydrate or solvate thereof.
4. The method of claim 1 wherein the compound is 8,8-dipropyl-2- azaspiro[4.5]decane-2-(4-piperidine); or a pharmaceutically acceptable salt, hydrate or solvate thereof.
5. The method of claim 1 wherein the compound is administered orally.
6. The method of claim 5 wherein from about 0.01 mg/kg to about 10 mg/kg of compound is administered per day.
7. The method of claim 1 wherein the compound is administered parenterally.
8. The method of claim 7 wherein from about 0.01 mg/kg to about 10 mg/kg of compound is administered per day.
9. The method of claim 1 wherein the compound is administered topically.
10. The method of claim 9 wherein from about 0.01 mg/kg of about 10 mg/kg of compound is administered per day.
11. A pharmaceutical composition for use in treatment of psoriasis in a mammal in need thereof comprising a

 in which: m is 1 or 2;
R! and R^ are the same or different and are selected from hydrogen or straight or branched chain alkyl, provided that the total number of carbon atoms contained by R
1
 and R^ when taken together is 4-10; or R* and R^ together form a cyclic alkyl group containing 3-7 carbon atoms; 


/04151
20
A is absent or present as C\-Cη alkyl; and
R3 is a heterocyclic or heterobicyclic ring, said heterocyclic or heterobicyclic ring thereby containing up to 10 carbon atoms and from 1-3 heteroatoms of the formula NR^, where R^ is absent or present as hydrogen, or a straight chain alkyl containing 1-3 carbon atoms; or a pharmaceutically acceptable salt, hydrate or solvate thereof and a pharmaceutically acceptable carrier.
12. A composition according to claim 11 wherein the mammal being treated is a human.
13. A composition according to claim 11 wherein the compound is selected from:

 or a pharmaceutically acceptable salt, hydrate or solvate thereof.
14. A composition according to claim 11 wherein the compound is 8,8-dipropyl-
2-azaspiro[4.5]decane-2-(4-piperidine); or a pharmaceutically acceptable salt, hydrate or solvate thereof. 



 15. A composition according to claim 11 wherein the compound is administered orally.
16. A composition according to claim 15 wherein from about 0.01 mg/kg to about 10 mg/kg of compound is administered per day.
17. A composition according to claim 11 wherein the compound is administered parenterally.
18. A composition according to claim 17 wherein from about 0.01 mg/kg to about 10 mg/kg of compound is administered per day.
19. A composition according to claim 11 wherein the compound is administered topically.
20. A composition according to claim 19 wherein from about 0.01 mg/kg of about 10 mg/kg of compound is administered per day.
21. Use of a compound of the formula

 in which: m is 1 or 2;
R! and R^ are the same or different and are selected from hydrogen or straight or branched chain alkyl, provided that the total number of carbon atoms contained by R^ and R^ when taken together is 4-10; or R* and R^ together form a cyclic alkyl group containing 3-7 carbon atoms;
A is absent or present as Cj-Cγ alkyl; and
R3 is a heterocyclic or heterobicyclic ring, said heterocyclic or heterobicyclic ring thereby containing up to 10 carbon atoms and from 1-3 heteroatoms of the formula NR^, where R^ is absent or present as hydrogen, or a straight chain alkyl containing 1-3 carbon atoms; or a pharmaceutically acceptable salt, hydrate or solvate thereof in the manufacture of a medicament for use in the treatment of psoriasis in a mammal in need thereof.
22. A use according to claim 21 wherein the mammal being treated is a human. 


 22
23. A use according to claim 21 wherein the compound is selected from:
or a pharmaceutically acceptable salt, hydrate or solvate thereof.
24. A use according to claim 21 wherein the compound is 8,8-dipropyl-2- azaspiro[4.5]decane-2-(4-piperidine); or a pharmaceutically acceptable salt, hydrate or solvate thereof.
25. A use according to claim 21 wherein the compound is administered orally.
26. A use according to claim 25 wherein from about 0.01 mg/kg to about 10 mg/kg of compound is administered per day.
27. A use according to claim 21 wherein the compound is administered parenterally. 


28. A use according to claim 27 wherein from about 0.01 mg/kg to about 10 mg/kg of compound is administered per day.
29. A use according to claim 21 wherein the compound is administered topically.
30. A use according to claim 29 wherein from about 0.01 mg/kg of about 10 mg/kg of compound is administered per day. 


</CLAIMS>
</TEXT>
</DOC>
